Author of

• 31105

  +

  P2.06 - Mesothelioma (ID 170)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Mesothelioma
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 31126

    +

    P2.06-21 - Efficacy and Safety of Tumor Treating Fields Delivery to the Thorax by Computational Simulations (ID 2354)

    10:15 - 18:15  |  Author(s): Noa Urman
    • Abstract
    • Slides

    Background
    

    Tumor Treating Fields (TTFields), an anti-mitotic therapy low intensity, intermediate frequency, alternating electric fields, are approved for glioblastoma. The STELLAR phase 2 registration trial recently demonstrated a significant extension in overall survival in mesothelioma patients treated with TTFields and standard of care chemotherapy vs historical control data on chemotherapy alone. The results highlight the potential benefit of TTFields to treat cancer located in the thorax.

    Preclinical studies show that efficacy increases with the intensity of the electric field. Optimizing treatment requires a thorough understanding of how TTFields distribute within the body. Simulations can be used to evaluate the treatment safety by assessing tissue heating associated with absorption of the electric field. We present a simulation based study on field distribution and associated heating when delivering TTFields to the thorax.

    Method
    

    We delivered TTFields to the thorax of realistic computational phantoms of a male, female, and obese male (ZMT, Zurich, Switzerland). The field was delivered to the computational phantoms using transducer arrays similar to those used to deliver TTFields to the thorax with the NovoTTF-100L. The field intensities within the lungs of the models were evaluated. Specific Absorption Rate (SAR), a metric for assessing heating due to electromagnetic absorption, was calculated.

    Result
    

    The highest field intensities within the lungs were obtained when the arrays were axially-aligned with the parenchyma as anatomically possible. Field intensities throughout the lungs exceeded the therapeutic threshold of 1 V/cm in all models. Within the internal organs, SAR values were below the allowed level of 10 W/kg set out in the ICNIRP guidelines for occupational exposure. Maximum SAR levels did not exceed 20 W/kg. Occupational exposure standards typically incorporate a safety factor of around 10 when setting basic restrictions, therefore this level of SAR is considered safe and unlikely to lead to heat-related tissue damage.

    Conclusion
    

    TTFields can be delivered to the lungs at therapeutic levels that do not cause damage through tissue heating.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.